New Shot-Based immunotherapy combo tested for advanced lung cancer

NCT ID NCT06946797

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This study tests two different dosing schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy, in people with advanced or recurrent non-small cell lung cancer who have not had prior treatment. The main goal is to measure drug levels in the blood and to check safety. About 76 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Local Institution - 0003

Suresnes, Hauts-de-Seine, 92151, France
Local Institution - 0009

Sandton, GP, 2196, South Africa
Local Institution - 0010

Paris, Île-de-France Region, 75014, France
Local Institution - 0011

Thessaloniki, Kentrikí Makedonía, 540 07, Greece
Local Institution - 0012

Athens, Attikí, 115 27, Greece
Local Institution - 0013

Chaïdári, Attikí, 12462, Greece
Local Institution - 0014

Larissa, Thessalía, 41110, Greece
Local Institution - 0015

Meldola, Emilia-Romagna, 47014, Italy
Local Institution - 0017

Novara, 28100, Italy
Local Institution - 0019

Florence, Tuscany, 50134, Italy
Local Institution - 0020

Bergamo, Lombardy, 24127, Italy
Local Institution - 0031

Soweto, Gauteng, 2013, South Africa
Local Institution - 0032

Anchorage, Alaska, 99508, United States
Local Institution - 0033

Cleveland, Ohio, 44109, United States
Local Institution - 0034

São Paulo, 01246-000, Brazil
Local Institution - 0037

Barretos, São Paulo, 14784400, Brazil
Local Institution - 0038

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Local Institution - 0041

Brasília, Federal District, 70200-730, Brazil
Local Institution - 0043

Belo Horizonte, Minas Gerais, 30380-490, Brazil
Local Institution - 0047

Cleveland, Ohio, 44106, United States
Local Institution - 0051

Allentown, Pennsylvania, 18103, United States
Local Institution - 0052

Boise, Idaho, 83706, United States
Local Institution - 0057

Udine, Friuli Venezia Giulia, 33100, Italy
Local Institution - 0062

Los Angeles, California, 90033, United States
Local Institution - 0063

Boise, Idaho, 83702, United States
Local Institution - 0064

Post Falls, Idaho, 83854, United States
Local Institution - 0065

Dijon, Côte-d'Or, 21079, France
Local Institution - 0067

Santiago, Santiago Metropolitan, 8420383, Chile
Local Institution - 0073

Bucharest, Bucharest, 022328, Romania
Local Institution - 0074

Cluj-Napoca, 400015, Romania
Local Institution - 0075

Bucharest, 020335, Romania
Local Institution - 0076

Florești, Cluj, 407280, Romania
Local Institution - 0077

Craiova, Dolj, 200542, Romania
Local Institution - 0078

Iași, 700483, Romania
Local Institution - 0079

Lodz, Łódź Voivodeship, 93-338, Poland
Local Institution - 0080

Prabuty, Pomeranian Voivodeship, 82-550, Poland
Local Institution - 0081

Warsaw, Masovian Voivodeship, 03-411, Poland
Local Institution - 0084

Rondebosch, Western Cape, 7700, South Africa

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER